Free Trial
Memorial Day Savings! Save $100 on MarketBeat All Access
Claim Your Discount
Claim MarketBeat All Access Sale Promotion
Narumi Nakagiri

Narumi Nakagiri Analyst Performance

Director at Daiwa Securities Group

Narumi Nakagiri is a stock analyst at Daiwa Securities Group in the medical sector, covering 2 publicly traded companies. Over the past year, Narumi Nakagiri has issued 5 stock ratings, including buy and hold recommendations. While full access to Narumi Nakagiri's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Narumi Nakagiri's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
5 Last 0 Years
Buy Recommendations
50.00% 2 Buy Ratings
Companies Covered
2 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy50.0%2 ratings
Hold50.0%2 ratings
Sell0.0%0 ratings

Out of 4 total stock ratings issued by Narumi Nakagiri at Daiwa Securities Group, the majority (50.0%) have been Buy recommendations, followed by 50.0% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NYSE
100.0% of companies on NYSE
2 companies

Narumi Nakagiri, an analyst at Daiwa Securities Group, currently covers 2 companies listed on , with the majority traded on NYSE.

Coverage Focus

Sector IconSectorPercentage
Medical
2 companies
100.0%

Narumi Nakagiri of Daiwa Securities Group specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
LARGE CAP PHARMA
1 company
50.0%
MED - BIOMED/GENE
1 company
50.0%

Narumi Nakagiri's Ratings History at Daiwa Securities Group

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2/18/2026Boost Price Target$1,022.60$1,250.00Buy
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
12/16/2025Set Price Target$1,062.67$1,230.00Buy
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
11/10/2025Boost Price Target$1,024.67$940.00
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
8/17/2025Downgrade$701.51$700.00Neutral
Bristol Myers Squibb Company stock logo
BMY
Bristol Myers Squibb
8/5/2025Downgrade$45.39$42.00Neutral